Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 19/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30186863 | 1.00 | ERN1 (1.00) | ERN1KDM4ENPC1ALDH1A1RAB9A | |
| SCHEMBL12767181 | 1.00 | ERN1 (1.00) | ERN1KDM4ENPC1ALDH1A1RAB9A | |
| SCHEMBL18717265 | 0.89 | ERN1 (0.80) | ERN1KDM4ENPC1ALDH1A1RAB9A | |
| SCHEMBL12674887 | 0.88 | ERN1 (0.78) | ERN1 | |
| SCHEMBL1527526 | 0.88 | ERN1 (1.00) | ERN1NPC1ALDH1A1RAB9A | |
| SCHEMBL12674895 | 0.88 | ERN1 (0.78) | ERN1 | |
| SCHEMBL12674860 | 0.84 | ERN1 (0.72) | ERN1 | |
| SCHEMBL12674899 | 0.83 | ERN1 (0.71) | ERN1 | |
| SCHEMBL12674866 | 0.82 | ERN1 (0.82) | ERN1 | |
| SCHEMBL12675806 | 0.82 | ERN1 (0.69) | ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 349 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240301429-A1 | COMPOSITIONS COMPRISING SASP MODULATORS AND SENESCENCE ATTENUATORS AND USES THEREOF FOR MODULATING CELLULAR SENESCENCE | RSEM, LIMITED PARTNERSHIP (CA) | 2024-09-12 | — | — | US | claimed |
| US-20240216346-A1 | Substituted Chromenones, IRE1 Inhibitors, and Methods of Using Same | THE WISTAR INST (US) | 2024-07-04 | — | — | US | claimed |
| US-20230190745-A1 | USE OF METABOLIC REGULATORS FOR THE TREATMENT OF COVID-19 | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-06-22 | — | — | US | claimed |
| WO-2023023538-A2 | TREATING TISSUE INFLAMMATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2023-02-23 | — | — | WO | claimed |
| US-20220105061-A1 | COMPOSITIONS AND METHODS FOR TREATING RESPIRATORY INSUFFICIENCY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-07 | — | — | US | claimed |
| US-20220023291-A1 | COMPOSITIONS AND METHODS FOR REGULATING INFLAMMATION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-01-27 | — | — | US | claimed |
| US-20260144799-A1 | COMPOSITION COMPRISING A FIRST RAS INHIBITOR, SECOND RAS INHIBITOR AND A SHP2 INHIBITOR FOR USE IN THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2026-05-28 | — | — | US | disclosed |
| US-12637445-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2026-05-26 | — | — | US | disclosed |
| WO-2026106912-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4743080-A2 | METHODS OF TREATING A RAS RELATED DISEASE OR DISORDER | Revolution Medicines, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12624053-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2026-05-12 | — | — | US | disclosed |
| WO-2026090245-A1 | USE OF RAS INHIBITORS FOR TREATING CANCER | Revolution Medicines, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026090127-A1 | METHODS OF TREATING A RAS PROTEIN-RELATED DISEASE OR DISORDER | Revolution Medicines, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-11274105-B2 | Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonists | AMGEN INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20220073504-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2022-03-10 | — | — | US | disclosed |
| WO-2022044014-A1 | COMBINATION THERAPY FOR REDUCING DRUG-INDUCED NEPHROTOXICITY, DYSLIPIDEMIA AND HYPERGLYCEMIA | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2022-03-03 | — | — | WO | disclosed |
| US-20220056015-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2022-02-24 | — | — | US | disclosed |
| US-11236069-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20220023341-A1 | USE OF IRE1ALPHA-XBP1 SIGNALING PATHWAY BIOMARKERS FOR MODULATING IMMUNE RESPONSES | DANA-FARBER CANCER INSTITUTE, INC. | 2022-01-27 | — | — | US | disclosed |
| US-20220023291-A1 | COMPOSITIONS AND METHODS FOR REGULATING INFLAMMATION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624053-B2 | Ras inhibitors | KRAS, NRAS, HMGCR | ERN1 2285/4885KDM4E 2746/4885NPC1 139/4885 |
| US-20220073504-A1 | KIF18A INHIBITORS | KIF18A, KIF18B, KIF15 | ERN1 1884/4885KDM4E 1625/4885NPC1 649/4885 |
| US-12637445-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIF2C | ERN1 991/4885KDM4E 1178/4885NPC1 241/4885 |
| US-20260144799-A1 | COMPOSITION COMPRISING A FIRST RAS INHIBITOR, SECOND RAS INHIBITOR AND A SHP2 INHIBITOR FOR USE IN THE TREATMENT OF CANCER | PDCD1, CD274, PTPN1 | ERN1 2522/4885KDM4E 1387/4885NPC1 3307/4885 |
| US-20220023291-A1 | COMPOSITIONS AND METHODS FOR REGULATING INFLAMMATION | SIGMAR1, OPRL1, FPR1 | ERN1 1356/4885KDM4E 4571/4885NPC1 1999/4885 |
| US-11274105-B2 | Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonists | MCL1, BCL2A1, BCLAF1 | ERN1 1406/4885KDM4E 3326/4885NPC1 1954/4885 |
| US-11236069-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIF15 | ERN1 2097/4885KDM4E 1372/4885NPC1 633/4885 |
| US-20220056015-A1 | KIF18A INHIBITORS | KIF18A, KIF18B, KIF15 | ERN1 2256/4885KDM4E 1251/4885NPC1 917/4885 |
| US-20240216346-A1 | Substituted Chromenones, IRE1 Inhibitors, and Methods of Using Same | XBP1, ERN1, ERN2 | ERN1 2/4885KDM4E 1034/4885NPC1 2578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.